IN2014DN00145A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00145A
IN2014DN00145A IN145DEN2014A IN2014DN00145A IN 2014DN00145 A IN2014DN00145 A IN 2014DN00145A IN 145DEN2014 A IN145DEN2014 A IN 145DEN2014A IN 2014DN00145 A IN2014DN00145 A IN 2014DN00145A
Authority
IN
India
Prior art keywords
solid forms
amide
pharmaceutical compositions
present
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Isabelle Sylvie Gallou
Cornelius Gauer
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN00145A publication Critical patent/IN2014DN00145A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN145DEN2014 2011-06-21 2012-06-19 IN2014DN00145A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161499222P 2011-06-21 2011-06-21
PCT/EP2012/061756 WO2012175522A1 (fr) 2011-06-21 2012-06-19 Polymorphes du 2-amide-1-({4-méthyl-5-[2-(2,2,2-trifluoro-1,1-diméthyl- éthyl)pyridin-4-yl]-thiazol-2-yl}-amide d'acide (s)-pyrrolidine-1,2-dicarboxylique

Publications (1)

Publication Number Publication Date
IN2014DN00145A true IN2014DN00145A (fr) 2015-05-22

Family

ID=46319784

Family Applications (1)

Application Number Title Priority Date Filing Date
IN145DEN2014 IN2014DN00145A (fr) 2011-06-21 2012-06-19

Country Status (11)

Country Link
US (1) US9006270B2 (fr)
EP (1) EP2723733A1 (fr)
JP (1) JP2014517049A (fr)
KR (1) KR20140033432A (fr)
CN (1) CN103619840B (fr)
BR (1) BR112013032687A2 (fr)
CA (1) CA2839621A1 (fr)
IN (1) IN2014DN00145A (fr)
MX (1) MX2013014887A (fr)
RU (1) RU2014101626A (fr)
WO (1) WO2012175522A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
CA2865993A1 (fr) * 2012-03-30 2013-10-03 Novartis Ag Composes pour utilisation dans le traitement de neuroblastome, sarcome d'ewing ou un rhabdomyosarcome
CN105979947A (zh) * 2013-12-06 2016-09-28 诺华股份有限公司 α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
PL3200772T3 (pl) * 2014-10-03 2022-12-19 Novartis Ag Kompozycje farmaceutyczne zawierające alpelisyb
EP3956330A4 (fr) 2019-04-18 2023-01-18 The Johns Hopkins University Dérivés de 2-amino-pyrazolyl-[1,2,4]triazolo[1,5 a] pyridine substitués et leur utilisation
CN112961090A (zh) * 2019-12-13 2021-06-15 武汉九州钰民医药科技有限公司 合成Alpelisib的关键中间体及其制备方法
CN110964005A (zh) * 2019-12-16 2020-04-07 武汉九州钰民医药科技有限公司 一种Alpelisib的制备工艺
CN111057051A (zh) * 2019-12-16 2020-04-24 武汉九州钰民医药科技有限公司 PI3K抑制剂Alpelisib的新合成方法
JP2022061050A (ja) 2020-10-06 2022-04-18 エルジー ディスプレイ カンパニー リミテッド 伝送装置及び表示システム
CN117279627A (zh) * 2021-05-03 2023-12-22 诺华股份有限公司 阿培利司配制品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
EP2016075A1 (fr) * 2006-05-03 2009-01-21 AstraZeneca AB Dérivés de thiazole et leur utilisation comme agents anti-tumoraux
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Also Published As

Publication number Publication date
EP2723733A1 (fr) 2014-04-30
CN103619840B (zh) 2016-01-20
RU2014101626A (ru) 2015-07-27
CA2839621A1 (fr) 2012-12-27
JP2014517049A (ja) 2014-07-17
US9006270B2 (en) 2015-04-14
AU2012274141A1 (en) 2013-12-12
KR20140033432A (ko) 2014-03-18
BR112013032687A2 (pt) 2016-08-30
AU2012274141B2 (en) 2015-12-24
US20140171470A1 (en) 2014-06-19
CN103619840A (zh) 2014-03-05
MX2013014887A (es) 2014-02-17
WO2012175522A1 (fr) 2012-12-27

Similar Documents

Publication Publication Date Title
IN2014DN00145A (fr)
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
ZA201201791B (en) Method for the preparation of 2,5-furandicarboxylic acid and esters thereof
ZA201201974B (en) Method for the preparation of 2,5-furandicarboxylic acid and for the prepartion of the dialkyl ester of 2,5-furandicarboxylic acid
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2013005292A (es) Sal (es) de dimetil-amida del acido 7-ciclopentil-2- (5-piperazin-1-il-piridin-2-il-amino) -7h-pirrolo- [2, 3-d]-pirimidin-6-carboxilico y procesos para su elaboracion.
EA020703B9 (ru) Пиразолохиназолины
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MX2015004947A (es) Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
IN2014CN03597A (fr)
IN2015DN01151A (fr)
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
PT2429507T (pt) Composição farmacêutica isenta de fosfatos para o tratamento do glaucoma
PH12017500089B1 (en) Aldosterone synthase inhibitors
IN2013DN02555A (fr)
CA2894715C (fr) Diazole amides
MX2012008413A (es) Composicion novedosa de retigabina.
MX339361B (es) Derivados de alternano.
SI2532651T1 (sl) Postopek sinteze in kristalinična oblika 4-(3-(cis-heksahidrociklopenta(c)pirol-2(1H)-il)propoksi) benzamid hidroklorida ter njegova prosta baza, pa tudi farmacevtski sestavki, ki ju vsebujejo
IN2013MN00811A (fr)
JO2851B1 (en) 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof.